American BriVision Holding Corp is a clinical stage bio pharmaceutical company. Its focus is on enhancing the already available pharmaceutical products for cancer and other diseases and commercialize the same.
| Website: | www.ambrivis.com |
| Email: | marty@mccloudcommunications.com |
| Main Phone: | +1 845 291-1291 |
| Address: | 11 Sawyers Peak Drive |
| State: | NY |
| City / Town: | Goshen |
| Country: | USA |
| Postal Code: | 10924 |
| Exchange: | OTCQB |
| CEO: | Robert G. Crockett |
| Employees: | 9 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 1.65 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close 1.65 |
| Last Trade | Volume 0 | 52 Wk Hi 2.00 | 52 Wk Low 1.65 |
| Market Cap 353 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 213,926,475.00 | EPS (TTM) -0.02 | PE Ratio N/A | Exchange OTCQB |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| RW | Withdrawal of registration statement filed under the Securities Act | 1 | 2018-06-12 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 34 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-10 |
| 10-KT | Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act | 74 | 2018-04-13 |
| NT 10-K | Notification that form 10-K will be submitted late | 3 | 2018-04-03 |
| 10-Q/A | Amendment to a previously filed 10-Q | 37 | 2018-03-19 |
| 10-Q/A | Amendment to a previously filed 10-Q | 37 | 2018-03-19 |
| 10-Q/A | Amendment to a previously filed 10-Q | 28 | 2018-03-19 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-03-12 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-02-14 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
